The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
|Articles|January 19, 2021
TS Alliance E-Webinar Series
Author(s)Neurology Times Staff
A look into the numerous education series upcoming in 2021 by the Tuberous Sclerosis Alliance
Advertisement
This content is courtesy of the Tuberous Sclerosis Alliance. To view the original post,
For 2021, the TS Alliance will host monthly educational webinars on a variety of TSC related topics of interest featuring known experts in the TSC community. These free 1-hour presentations include an open question-and-answer period. This series is composed of educational webinars focusing on four topic areas:
Life Stages of TSC (epilepsy, tumor growth, skin manifestations and education)
- Transition Workshops
- TSC-Associated Neuropsychiatric Disorders (TAND)
- Research Updates/Clinical Trials
For more information and to register online, visit
Advertisement
Related to this article
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Xenon Pharmaceuticals submitted an FDA new drug application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
2
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
3
NeurologyLive® Brain Games: September, 2026
4
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
5